Aromatase Inhibitor(AI) therapy is a crucial treatment for regulating estrogen production that combats breast cancer in postmenopausal patients. Clinical trials have emphasized its importance, as it has surpassed its prior efficacy through each succeeding generation of AI therapy and surpassed other treatment options like estrogen modulators(Tamoxifen) and Progestin therapy(Megace/Megestrol Acetate). There is a big difference between AI therapy and other therapies, though they all ultimately attempt to stop the proliferation of cancerous cells. AI therapy has been shown to be effective; however, some side effects of its use have been challenging its place in recent studies. Many physicians have noticed and questioned its use, and future research addressing these concerns needs to be executed in order to enhance the quality of life for our breast cancer patients. In this paper, an overview of the current status of breast cancer, the details of breast cancer and its development, the different types of breast cancer, the workings of AI therapy, clinical trials of Aromatase Inhibitor therapy, a comparison of different therapies, Physician input, and future implications of its effectiveness will be discussed in detail.